Io­n­is chops two PhII pro­grams in acromegaly and be­ta tha­lassemia

Io­n­is Phar­ma­ceu­ti­cals is cut­ting two pro­grams — a can­di­date for acromegaly and one for be­ta tha­lassemia — ac­cord­ing to its fist quar­ter earn­ings re­port Wednes­day af­ter­noon. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER